Landmark Study Shows Benefits of Eprodisate (KIACTA(TM)) Treatment

05102237

Neurochem (International) Limited, a wholly-owned subsidiary of Neurochem Inc. (Laval), announced that the New England Journal of Medicine (NEJM) published the results of the \"Eprodisate For AA Amyloidosis Trial\" (EFAAT), recognized as a landmark clinical trial in the search for a treatment of AA amyloidosis. The results of the Phase II/III clinical trial for eprodisate (KIACTA(TM)) demonstrate that this product candidate offers important clinical benefits to patients by reducing the progression of AA amyloidosis-associated renal disease. The results from the EFAAT have been submitted to the U.S. Food and Drug Administration, the European Medicines Agency and Swissmedic in support of applications for marketing approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis, a disease which remains without a specific treatment. The print issue of the publication will be available in the June 7, 2007 issue of the NEJM. The article entitled \"Eprodisate for the Treatment of Renal Disease in AA Amyloidosis\" is accessible online, and can be found at http://www.nejm.org under the \"Current Issue\" section of the Web site. http://www.neurochem.com